Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 401-411

  Aghokeng, Avelin F ^a   Vergne, Laurence ^b   Mpoudi Ngole, Eitel ^a   Mbangue, Madeleine ^c   Deoudje, Noe ^d   Makondji, Etienne ^e   Nambei, Wilfrid S ^f   Peyou Ndi, Marlyse M ^g   Moka, Jean Jacques ^g   Delaporte, Eric ^b   Peeters, Martine ^b  

^a IMPM/Institut de Recherche pour le Developpement (IRD)   (Cameroon)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c Hopital Laquintinie   (Cameroon)

^d INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^e Laboratoire National de la Santé Publique   (Congo)

^f Laboratoire National de Biologie   (South Africa)

^g Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CAMEROON; CENTRAL AFRICAN REPUBLIC; CHAD; CONGO; FEMALE; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AFRICA, CENTRAL; ANTI-HIV AGENTS; DATA COLLECTION; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PREGNANCY; PREVALENCE; PROGRAM EVALUATION; REVERSE TRANSCRIPTASE INHIBITORS; WORLD HEALTH ORGANIZATION;

EID: 67649188260     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. UNAIDS, WHO. AIDS epidemic update: December 2007. (Accessed 26 July 2008.) Available from http://data.unaids.org/pub/EPISlides/2007/ 2007_epiupdate_en:pdf
2. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector. Progress report, April 2007. (Accessed 26 July 2008.) Available from http://data.unaids.org/pub/ Report/2007/20070925_oms_progress_report_en.pdf
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
4. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29:510-517.
5. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). (Accessed 26 July 2008.) Available from http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf
6. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005; 21:343-357.
7. Little SJ, Holte S, Roury JP, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
8. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant: dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-1038.
9. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006; 19:607-614.
10. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral, treatment. Antivir Ther 2008; 13 Suppl 2:25-36.
11. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 Suppl 2:15-23.
12. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use anq HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002; 29:165-168.
13. Maslin J, Rogier C, Caron M, Grandadam M, Koeck JL, Nicand E. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir Ther 2005; 10:855-859.
14. Konings FAJ, Zhong P, Agwara M, et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses 2004; 20:105-109.
15. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-579.
16. Adje-Toure C, Bile CE, Borget MY, et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2003; 34:111-113.
17. Ndembi N, Abraha A, Pilch H, et al. Molecular characterization of human immunodeficiency virus type 1 (HTV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008; 46:177-184.
18. Harriers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13:625-639.
19. Organisation de Coordination our la lutte contre les Endemies en Afrique Centrale (OCEAC). (Updated 15 April 2009. Accessed 4 May 2009.) Available from www.oceac.org
20. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925.
21. Eshleman SH, Hackett J, Jr, Swanson P, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 2004; 42:2711-2717.
22. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25:4876-4882.
23. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
24. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008; 13 Suppl 2:37-48.
25. Maes B, Schrooten Y, Snoeck J, et al. Performance of ViroSeq HrV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods 2004; 119:45-49.
26. Vidal N, Koyalta D, Richard V, et al. High genetic diversity of HIV-1 strains in Chad, West Central Africa. J Acguir Immune Defic Syndr 2003; 33:239-246.
27. Vergne L, Bourgeois A, Mpoudi-Ngole E, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 2003; 310:254-266.
28. UNAIDS. 2008 Progress reports submitted by countries. 2008. (Accessed 14 November 2008.) Available from http://www.unaids.org/en/KnowledgeCentre/ HIVData/CountryProgress/2007CountryProgressAllCountries.asp
29. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS 2007; 21:768-771.
30. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
31. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 Suppl 2:101-107.
32. Halvas EK, Aldrovandi GM, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44:2612-2614.
33. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 Suppl 2:115-121.
34. Sirivichayakul S, Phanuphak P, Pankam T, O-Charoen R, Sutherland D, Ruxrungtham K. HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther 2008; 13 Suppl 2:109-113.
35. UNAIDS. 2006 Report on the global AIDS epidemic: executive summary. (Accessed 9 December 2007.) Available from http://data.unaids.org/pub/ GlobalReport/2006/2006_GR-ExecutiveSummary_en.pdf